MIRM Share Price Performance
US$92.38
50.35 (119.80%)
13.3% undervalued intrinsic discount
US$106.60
Fair Value
Price US$92.38
AnalystConsensusTarget US$106.60
AnalystHighTarget US$140.00
AnalystLowTarget US$95.00
Fair ValueUS$106.60
Share Pricen/a
Mirum Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 21 Fair Values set on narratives written by author
MIRM Community Narratives
AN
Fair Value US$106.6 11.7% undervalued intrinsic discount
Upcoming Clinical Milestones Will Drive Rare Disease Pipeline Expansion Into 2026
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
Fair Value US$140 32.7% undervalued intrinsic discount
Genetic Testing And Global Launches Will Expand Rare Disease Access
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$95 0.9% undervalued intrinsic discount
Patent Expiry And Payer Pressures Will Check Future Performance
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Genetic Testing And Global Launches Will Expand Rare Disease Access
Key Takeaways Expanded patient identification and accelerated adoption of therapies are driving growth beyond market expectations, with international markets providing significant additional revenue potential. Advances in diagnostics and a strong financial position enable Mirum to extend treatment durations, acquire new assets, and maintain robust profitability and pricing power.Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$140
32.7% undervalued intrinsic discount
Fair Value
Profit Margin
26.14%
Future PE
40.68x
Price in 2029
US$170.17
Patent Expiry And Payer Pressures Will Check Future Performance
Key Takeaways Intensifying cost controls and payer scrutiny threaten long-term revenue, especially as rare disease therapy reimbursement becomes increasingly difficult in US and international markets. Competitive pressures from generics, shifting treatment paradigms, and high regulatory risk will limit market share, profitability, and future revenue growth.Read more
17
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$95
0.9% undervalued intrinsic discount
Fair Value
Profit Margin
12.13%
Future PE
61.2x
Price in 2029
US$116.04
Upcoming Clinical Milestones Will Drive Rare Disease Pipeline Expansion Into 2026
Key Takeaways Broader patient identification, international expansion, and supportive reimbursement environments are driving sustained revenue growth and improving margins for Mirum's portfolio. Advancing late-stage pipeline programs and leveraging precision medicine support future product expansion, revenue diversification, and long-term earnings acceleration.Read more
163
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
US$106.6
11.7% undervalued intrinsic discount
Fair Value
Profit Margin
16.92%
Future PE
53.5x
Price in 2029
US$130.67
Trending Discussion
Recently Updated Narratives
AN
MIRM: 2026 Clinical Readouts And Guidance Will Reframe Earnings Power Narrative
Fair Value: US$140 32.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
MIRM: Elevated Expectations Will Hinge On Upcoming PSC Trial Outcome
Fair Value: US$95 0.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
MIRM: Fair Value Tied To 2026 PSC Data And Execution Risks
Fair Value: US$106.6 11.7% undervalued intrinsic discount
13 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Mirum Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.39
- 80.77%
- -4.48%
- 98.4%
About MIRM
- Founded
- 2018
- Employees
- 371
- CEO
- WebsiteView website
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
